Multifactorial Intervention in Type 2 Diabetes - Italy (MINDIT)
Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes
Sponsor: AstraZeneca
Listed as NCT01240070, this PHASE4 trial focuses on Type 2 Diabetes and remains ongoing. Sponsored by AstraZeneca, it has been updated 7 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Mar 2024 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jan 2021 — Mar 2024 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Sep 2017 [monthly]
Unknown Status PHASE4
First recorded
Jan 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Daiichi Sankyo
- Italian Society of Diabetology
- University of Parma
For direct contact, visit the study record on ClinicalTrials.gov .